{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"Progression free survival was defined as time from start date of treatment to the date of first documentation of PD or death due to any cause. PD was defined as 20% increase in the sum of diameters of target measurable lesions above the smallest sum observed (over baseline if no decrease in the sum was observed during therapy), with a minimum absolute increase of 5 mm and unequivocal progression of pre-existing lesions.","groups":[{"description":"Participants were planned to receive PF-07263689 in combination with sasanlimab at the preliminary combination recommended Phase 2 dose from Part 1B.","id":"OG000","title":"Part 2: PF-07263689 + Sasanlimab"}],"populationDescription":"Data was not collected as no participants were enrolled in Part 2 of the study due to study termination.","reportingStatus":"POSTED","timeFrame":"From start date of treatment to the date of first documentation of PD or death due to any cause (up to 2 years)","title":"Part 2: Progression Free Survival","type":"SECONDARY"}